Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clearside Biomedical excels in 2022, eyes trial milestones and partnerships

Clearside Biomedical's strong performance in 2022, supported by key achievements and financial stability, positions the company well for future growth and innovation.
While facing challenges such as trial design adjustments and addressing analyst inquiries, Clearside's strategic partnerships and upcoming trials offer significant opportunities for expansion and market advancement.

Clearside Biomedical reports positive OASIS trial results and financial stability

Clearside Biomedical's Q1 2023 performance reflects advancements in CLS-AX development and financial stability
Challenges include addressing analyst inquiries and potential resistance to extended duration treatments
Opportunities lie in leading treatment innovation and expanding investor engagement through conferences and filings

Clearside Biomedical advances in wet AMD treatment with innovative approach

Clearside Biomedical's Q2 2023 earnings call highlighted strong progress in their lead program, financial stability, and innovative delivery technology, positioning them well in the market.
The company's differentiated mechanistic approach and potential for combination therapies offer competitive advantages and opportunities for market expansion.
While facing challenges in proving efficacy, financial sustainability, and market adoption, Clearside's strategic collaborations and diverse portfolio present avenues for growth and success.

Clearside Biomedical advances trials and partnerships, eyes growth opportunities

Clearside Biomedical's Q3 2023 Earnings Call highlighted progress in trials, partnerships, and cash position. Challenges include trial enrollment and design considerations, while opportunities exist in value creation and milestone achievements by partners.

Clearside Biomedical reports positive 2023 progress and financial stability

Clearside Biomedical made significant progress in 2023, with a focus on advancing key clinical programs and collaborations.
Financially, the company is well-positioned with sufficient resources to support operations until the third quarter of 2025.
Challenges lie in successfully completing ongoing trials and maintaining competitiveness in the evolving landscape of vision treatments.
Opportunities abound in innovative drug delivery approaches, therapeutic advancements, and strategic collaborations for Clearside.

Clearside Biomedical reports stable finances and bullish outlook on CLS-AX

Clearside Biomedical's Q1 2024 earnings call highlighted a stable financial position, key leadership additions, and the promising potential of CLS-AX in treating retinal diseases. Analyst inquiries underscored areas of interest and scrutiny, pointing to the company's need for continued strategic development and adherence to regulatory standards.

Clearside Biomedical reports positive trial results and strategic leadership changes

Clearside Biomedical's Q3 2024 earnings call highlighted promising trial results, financial stability, and strategic leadership changes.
The company's strengths lie in its innovative suprachoroidal platform, strong partnerships, and positive trial outcomes for wet AMD treatment.
While facing challenges in trial design and funding, Clearside Biomedical has opportunities in geographic atrophy treatment and flexible dosing strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Companies Inc

XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid LAVAL, QC and ALPHARETTA, Ga., Oct. 25, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced that the U.S. Food and Drug Administration (FDA) has approved XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation1.

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

Multiple clinical data presentations demonstrate the potential of the suprachoroidal injection platform as a flexible, in-office, non-surgical procedure across multiple chorioretinal diseases Multiple clinical data presentations demonstrate the potential of the suprachoroidal injection platform as a flexible, in-office, non-surgical procedure across multiple chorioretinal diseases

Clearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) Annual Meeting

Innoviva

Mannatech

Oramed Pharmaceuticals

United Therapeutics

Veru

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Stocks To Invest in for October

ALPHARETTA, Ga., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple presentations were given at the Retina Society 54th Annual Scientific Meeting which took place September 29 – October 2, 2021 in Chicago, IL.

Clearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting

ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today completion of dosing in Cohort 2 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

– Increasing Global Awareness of Innovative Suprachoroidal Injection Platform – – Increasing Global Awareness of Innovative Suprachoroidal Injection Platform –

Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries

ALPHARETTA, Ga., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a company overview at the Ophthalmology Futures European 2021 Virtual Retina Forum on September 8, 2021. Access to the event is available here.

Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum

SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the licensed territory for ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension, known as XIPERE™ in the U.S.) from Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea to also include ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam) and India . ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) through Clearside's patented SCS Microinjector®.

Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2021 Results - Earnings Call Transcript

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 8.33% and 5.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Tops Revenue Estimates

Shares of Clearside Biomedical (NASDAQ:CLSD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 15.38% over the past year to ($0.11), which beat the estimate of ($0.12).

Clearside Biomedical: Q2 Earnings Insights

- Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial  with Data Expected by the End of 2021 –

Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Clearside is developing treatments for diseases of the suprachoroidal space of the eye. However, even its latest stage asset has very little monetary value.

Clearside's Value Proposition Is Far From Clear

ALPHARETTA, Ga., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in two upcoming investor conferences in August 2021:

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Clearside Biomedical, Inc. (CLSD) Report Negative Earnings Next Week? What You Should Know

ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2021 financial results will be reported on Tuesday, August 10, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

McEwen Mining

New Gold

NexGen Energy

PHX Minerals

Looking for the best penny stocks to watch right now? Check these 7 out The post Which Penny Stocks Are Investors Buying Right Now?

Which Penny Stocks Are Investors Buying Right Now? Check These 7 Out

Boxlight

ConforMIS

Protagenic Therapeutics

Uxin Ltd - ADR

In a recent pennystocks.com article, we covered 5 Penny Stocks on Reddit for Your June 2021 Watchlist. This piece is a continuation, as more and more valuable penny stocks continue to come to light. Right now, there are a lot of unique factors at play in the stock market. On one hand, we have the pandemic coming to an end.

Penny Stocks to Watch With AMC Stock Back in Focus

Analysts are excited about the biotech's investigational treatment for a common eye disorder.

Why Clearside Biomedical Stock Surged Today

Obalon Therapeutics

Tellurian

Looking for penny stocks to buy on Reddit? Check these 4 out for your watchlist The post 4 Penny Stocks Reddit Traders Are Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks Reddit Traders Are Buying Right Now

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

Do Options Traders Know Something About Clearside Biomedical (CLSD) Stock We Don't?

The stock price of Clearside Biomedical, Inc. (Nasdaq: CLSD) increased 37.75% yesterday. This is why it happened.

CLSD Stock Price Increased 37.75%: Why It Happened

Today, investors in CLSD stock are seeing gains of nearly 50% as the company announced positive results from one of its clinical trials. The post CLSD Stock: The Big News Lifting Clearside Biomedical Today appeared first on InvestorPlace.

CLSD Stock: The Big News Lifting Clearside Biomedical Today

Shares of Clearside Biomedical, Inc. (NASDAQ: CLSD) are skyrocketing Tuesday morning after the company announced positive safety results for a treatment for eye diseases. If Clearside makes it to the $4.25 level, there is a good chance that the rally stalls.

Where Will The Clearside Biomedical Stock Rally End?

The stock price of Clearside Biomedical Inc (NASDAQ: CLSD) increased by over 35% pre-market. This is why it happened.

News for Clearside Biomedical Stock (CLSD)